Recon: BMS to buy Mirati for up to $5.8 billion; Alnylam drops expanded indication for heart disease drug after FDA rejection

• FDA rejects Alnylam’s heart disease treatment over insufficient data (STAT)
• Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approval (Reuters)
• U.S. employers covering weight-loss drugs could nearly double in 2024 – survey (Reuters)
• Walmart expands online healthcare facility for US employees (Reuters)
• Bristol Myers Squibb buys Mirati for up to $5.8B as I-O giant branches out into targeted therapy for cancer (Fierce Pharma)

• Novo Nordisk's Wegovy bonanza looms large in Denmark (Reuters)
• Drugmaker Teva does not see big impact on business from Israel-Hamas war (Reuters)
• Contentious Pricing Mechanism Adopted In Canada But Only For ‘A Brief Period’ (Pink Sheet)
• Global Pharma Guidance Tracker – September 2023 (Pink Sheet)

• Want a biotech buyout? Target cancer (STAT)
• Akero’s treatment for NASH falls short in cirrhosis study (STAT)
• Merck says Keytruda improves survival before and after lung cancer surgery, awaits FDA decision next week (Endpoints)
• Bayer takes next step in cell therapy, opening new $250M facility in Berkeley (Endpoints)
• MarketingRx roundup: Pharma brands get creative on Instagram; J&J reups health equity challenge (Endpoints)
• Health tech is going through a hype cycle, and it’s not necessarily a bad thing, a new Bessemer report found: #HLTH23 (Endpoints)
• Verily lays out 'Chapter 3', streamlining its business under a new CEO and focusing on commercial side: #HLTH23 (Endpoints)
• Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver (Endpoints)
• CEPI puts $25M into Rift Valley fever vaccine; Gates invests in AI for scientists in Africa in equity bid (Endpoints)
• How CVS and Walgreens are becoming pharma’s new big advertising strategy (Endpoints)
• Ventyx unveils positive PhII ulcerative colitis data but stock is down 20% due to competitive space (Endpoints)
• ‘Transparency-Rx’: Meet The PBM Execs Breaking Rank And Backing Reforms (Pink Sheet)
• Regulatory tracker: Novartis' Cosentyx approved in IV form (Fierce Pharma)
• Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion (Fierce Pharma)

• How “Regulatory Sandboxes” Offer Hope For New Technologies That Don’t Fit The Regulatory Mold (MedTech Insight)
• To protect chickens from bird flu, researchers try to CRISPR in immunity (STAT)
• The ‘model-eat-model world’ of clinical AI: How predictive power becomes a pitfall (STAT)
• How doctors and nurses shape Google’s AI, DEA extends telehealth flexibilities (STAT)
• Sanofi adds another AI alliance, this time for biologics with Baidu CEO’s startup (Endpoints)
• Clinicians ‘love yet fear’ AI, say medtech leaders (MedTech Dive)
• J&J-backed HistoSonics gets de novo clearance for liver cancer treatment (MedTech Dive)
• Insulet wins preliminary injunction against EOFlow in patent suit (MedTech Dive)
• J&J could reach market-leading medtech growth after consumer spinoff: analysts (MedTech Dive)

• D.C. Court Strikes Down Copay Accumulator Rule (FDA Law Blog)
• Connecticut’s comptroller explains his thinking about GLP-1s for state employees (STAT)
• Former VA Secretary, Biogen Exec On IRA And Politics, Price Clamps In Europe (Pink Sheet)